Introduction
The deregulated activity of genes important for leukemic cell growth, survival and differentiation has often been imputed to aberrant transcription or post-translational modifications; however, there is increasing evidence that several disease processes including different types of cancer are often associated with alteration of the cellular mechanisms controlling processing, maturation, stability, nuclear export and/or translation of specific mRNA molecule(s) (reviewed in Harford and Morris, 1997) . Aberrant protein synthesis, which is now frequently associated with neoplastic transformation (Sonenberg, 1993; Rosenwald, 1996; Clemens and Bommer, 1999; Willis, 1999; Zimmer et al., 2000; Dua et al., 2001; Meric and Hunt, 2002) , may depend on altered expression/ activity of translation initiation or elongation factors, or ribosomal proteins, which determine the rate of translation (Pestova et al., 2001; Raught et al., 2001; Ruggero and Pandolfi, 2003) . For example, overexpression of elF4E, the initiation factor interacting with the cap structure, can transform cells (Lazaris-Keretzas et al., 1990) by increasing the translation of specific mRNAs (i.e. c-myc and cyclin D1) (Rosenwald et al., 1993; Sonenberg and Gingras, 1998; Gopalkrishnan et al., 1999) . There is also evidence indicating that the activity of eIF4E is negatively regulated by the interacting protein 4E-BP1 (Feigenblum and Schneider, 1996) , which functions as a repressor of mRNA translation and whose activity is suppressed by PI-3K/ Akt-generated signals (Gingras et al., 1999) . In addition to this general control of mRNA translation, specific mechanisms of translational regulation have been demonstrated to involve mRNAs with complex 3 0 UTR or 5 0 UTR; such UTRs typically include multiple AUGs or upstream ORFs, or IRES elements that may serve as docking sites for RNA binding proteins that mediate translational stimulation or repression (Gray, 1998; van der Velden and Thomas, 1999; Kozak, 2001; Meijer and Thomas, 2002; Prats and Prats, 2002; Kuersten and Goodwin, 2003; Kim et al., 2003; Han et al., 2003) . Not surprisingly, altered expression of several RNA binding proteins with translation-regulatory function has been shown in different primary tumor cells and cancer cell lines (van der Velden and Thomas, 1999; Derrigo et al., 2000; Shyu and Wilkinson, 2000; Holcik et al., 2003) .
By investigating the mechanisms of leukemic transformation of hematopoietic cells, we found that the expression and activity of several RNA binding proteins with different roles in the regulation of mRNA metabolism was altered by the p210 BCR/ABL oncoprotein of chronic myelogenous leukemia (CML) Trotta et al., 2003) .
The BCR/ABL oncoprotein promotes the leukemic transformation of hematopoietic stem cells through its deregulated tyrosine kinase activity; this activity is essential for the recruitment and the activation of multiple pathways that transduce signals leading to the reduced apoptosis susceptibility and enhanced proliferative potential typical of BCR/ABL-expressing cells (Cortez et al., 1995; Carlesso et al., 1996; Skorski et al., 1997; Sawyers, 1999; Zou and Calame, 1999) . CML is a biphasic myeloproliferative disorder (reviewed in Carella et al., 2001 ) that clinically ensues as a stable syndrome, the 'chronic phase', phenotypically characterized by the accumulation of late myeloid precursors and apparently normal neutrophils (Griffin et al., 1983; Kantarjian et al., 1992) . From this disease stage, CML usually progresses (after several years) into an acute and fatal stage, the 'blast crisis', that involves the clonal expansion of an immature population of myeloid blast cells, which, in addition to the markedly enhanced proliferative potential and reduced susceptibility to drug-induced apoptosis, also exhibit increased genomic instability, altered motility and trafficking, and differentiation arrest (Griffin et al., 1983; Bednarek et al., 1988; Cortez et al., 1995; Skorski et al., 1997; Deininger et al., 2000; Salesse and Verfaillie, 2002; Skorski, 2002) .
It is likely that several of the genetic alterations found in CML blast crisis (i.e. p53 genetic inactivation) contribute to this phenotype (Skorski et al., 1996a; Honda et al., 2000) ; however, it is also clear that expression of BCR/ABL plays an important role in this disease stage as the proliferation and survival of CML blast crisis cells remains dependent on BCR/ABL expression and activity (Druker et al., 1996; Skorski et al., 1996b; Kantarjian et al., 2002; Sawyers et al., 2002) .
Among the changes in gene expression found in primary mononuclear marrow cells from blast crisis CML patients and in BCR/ABL-transformed murine myeloid progenitors, there is enhanced expression of various RNA binding proteins (Figure 1 ). Such enhanced expression correlates with the levels of BCR/ ABL and is sensitive to treatment with the Abl kinase inhibitor imatinib mesylate (Perrotti et al., 1998 Iervolino et al., 2002; Trotta et al., 2003) . Different molecular mechanisms are responsible for such an increase and may involve the activation of a cascade of phosphorylation events leading to either enhanced gene transcription (hnRNP A2/B1, hnRNP K, JKTBP1, hnRNP Dl, Tra2b, RNPS1, EWSh, SC-35, Pabp2 and hnRNP H1) or increased protein stability (TLS/FUS, hnRNP A1, hnRNP E2 and La/SSB) (Perrotti et al., 2000 Iervolino et al., 2002; Trotta et al., 2003) (Figure 1 ). Increased expression of these RNPs correlates with increased activity, which may be regulated by different pathways. For example, hnRNP K mRNA expression and translation-inhibitory activity are enhanced by BCR/ABL via activation of the MAPK signaling pathway (Perrotti, 2004, manuscript in preparation) , while FUS expression and DNA/RNA binding activity requires phosphorylation by the BCR/ ABL-activated PKCbII (Perrotti et al., 1998) . PKCbIIdependent phosphorylation of FUS at serine 256 enhances protein stability by preventing proteasomedependent degradation (Perrotti et al., 2000) . Expression of hnRNP A1 is also increased in BCR/ABL-expressing cells and in primary CML blast crisis cells by posttranscriptional mechanisms . The nucleus-cytoplasm shuttling activity of hnRNP A1 appears to be important in BCR/ABL-dependent transformation as ectopic expression of a nucleuslocalised hnRNP A1 defective in nucleus-cytoplasmic shuttling in CD34 þ CML-AP cells led to decrease in growth factor-dependent colony formation . Moreover, cells expressing this hnRNP A1 mutant showed reduced levels of Bcl-X L mRNA and protein, consistent with the possibility that hnRNP A1 promotes Bcl-X L mRNA export . Indeed, in BCR/ABL cells hnRNP A1 is in complex with Bcl-X L mRNA and other mRNAs encoding proteins possibly important for BCR/ABL-dependent transformation (Perrotti, 2004, manuscript in preparation) .
Among the RNA binding proteins whose expression is regulated by BCR/ABL, there are some like La (SSB), hnRNP E2 (PCBP2 or a-CP2), hnRNP K and PABP2 with an established role as positive or negative regulator of the translation of specific eukaryotic mRNAs (Ostareck et al., 1997; Ostareck-Lederer et al., 1998; Holcik and Korneluk, 2000; Kahvejian et al., 2001; Kim et al., 2001; Trotta et al., 2003; Intine et al., 2003; Evans et al., 2003) .
Effect of BCR/ABL on mRNA translation
In blast crisis CML, there is aberrant expression of RNA binding proteins with a role in regulation of mRNA translation, and this may represent a mechanism whereby the p210 BCR/ABL oncoprotein achieves transformation of hematopoietic cells. A role of BCR/ ABL in translation regulation is further supported by the finding that BCR/ABL tyrosine kinase activity affects the polysome loading (and the translation efficiency) of several mRNAs that encode proteins involved in the regulation of cell proliferation, survival and differentiation. For example, treatment of BCR/ ABL-expressing cells with imatinib mesylate modifies the polysome/monosome distribution of several mRNAs (unpublished results). Interestingly, sequence analysis of these mRNAs revealed that almost 90% of them include in their 5 0 UTR certain elements (i.e. uORFs, multiple AUGs), which serve as targets for translational regulation. For example, c/ebpb and p53 mRNAs, both shown to undergo translational regulation (Raught et al., 1996; Fu et al., 1996; Lincoln et al., 1998; Fu et al., 1999; Timchenko et al., 1999; Yin et al., 2002; Mazan-Mamczarz et al., 2003; Calkhoven et al., 2000) and to be downregulated in BCR/ABL-transformed cells (Nowicki et al., 2003; Trotta et al., 2003) , were less abundant (by oligonucleotide array hybridization) in the polysome-associated mRNA fractions of untreated BCR/ABL-expressing cells (unpublished results), in which mdm2 mRNA levels were, instead, markedly increased (Trotta et al., 2003) . Accordingly, Northern blot hybridization of polysome-and monosome-associated RNA separated by linear sucrose gradient centrifugation revealed that mdm2 mRNA was predominantly in the polysome-associated fractions of BCR/ABL-expressing cells, whereas it was clearly shifted toward the monosome fractions after STI571 treatment (Trotta et al., 2003) . Further analysis revealed that increased mdm2 mRNA translation in BCR/ABL cells was dependent on the integrity of a 27-base nucleotide sequence of mdm2 mRNA (located between the second uORF and 36 nucleotide upstream of the main AUG) which specifically interacts with the La antigen (Trotta et al., 2003) .
The La/SSB protein plays an important role in enhancing resistance to apoptosis of BCR/ABL-transformed cells In BCR/ABL-expressing cells, the La antigen was identified as the protein that upon binding to the intercistronic region (exon 2) of mdm2 mRNA enhances its translation (Trotta et al., 2003) (Figure 2 ). La expression is markedly enhanced by BCR/ABL and correlates with that of MDM2 (Trotta et al., 2003) . Although La antigen is primarily localized in the nucleus, it is also present in the cytoplasm, and increases there under certain conditions (Fan et al., 1998; Wolin and Cedervall, 2002) . For example, in poliovirusinfected cells La is redirected to the cytoplasm, where it interacts with the 5 0 UTR of poliovirus mRNA to positively influence its translation (Maraia and Intine, 2001; Wolin and Cedervall, 2002 and references therein) .
In addition to multiple virus-derived mRNAs, La has also been reported to interact with cellular mRNAs. Recently, the La antigen was reported to activate IRESdependent translation of the immunoglobulin heavy chain binding protein (BiP) mRNA upon interaction with its 5 0 UTR (Kim et al., 2001) , and of the X-linked inhibitor of apoptosis (XIAP) mRNA (Holcik and Korneluk, 2000) . Interestingly, the only significant homology between mdm2 and BiP mRNA 5 0 UTRs is in a short core sequence conserved in human and mouse mdm2 5 0 UTR that corresponds to the region of interaction of BiP mRNA with La. In BCR/ABLtransformed cells, the segment of the mdm2 5 0 UTR that contains the region involved in binding with the La protein can enhance GFP expression when placed in front of the GFP coding sequence (our unpublished results); however, this segment did not function as IRES when driving GFP expression in BCR/ABL-expressing cells transduced with a bicistronic retrovirus (our unpublished results). This suggests that the La protein has a general role in the regulation of mRNA translation, besides controlling IRES-dependent translation (Wolin and Cedervall, 2002) . Indeed, two recent reports indicate that La can regulate translation of a specific subset of mRNAs, the TOP mRNAs, which contain a terminal oligopyrimidine tract sequence in their 5 0 UTR (Cardinali et al., 2003; Intine et al., 2003) . In support of a more global role of La as regulator of mRNA translation, expression of XIAP was downmodulated in STI571-treated BCR/ABL-expressing cells (Fang et al., 2000) , suggesting that, in these cells, MDM2 and XIAP levels might be in part coregulated by La. Consistent with this, La is abundant in CML blast crisis primary samples and its levels appear to correlate with BCR/ABL levels and tyrosine kinase activity. Thus, La is a bona fide positive regulator of mdm2 translation because: (i) it recognizes a specific conserved sequence tract in mdm2 mRNA that is required for efficient MDM2 expression in vitro and in vivo ( The fact that La-mediated effect on MDM2 expression is functionally relevant for BCR/ABL leukemogenesis is indicated by the changes in susceptibility of BCR/ ABL-expressing cells to adriamycin-induced apoptosis, as wild-type La-overexpressing cells were more resistant than parental cells, whereas cells expressing dominantnegative La were more sensitive. Although MDM2 levels were markedly downmodulated in BCR/ABL cells expressing the dominant-negative La, these cells neither exhibited spontaneous apoptosis nor altered cell cycle activity, consistent with the primary role of MDM2 as a regulator of p53. Binding of the La protein to the mdm2 mRNA 5 0 UTR was also observed in v-Src-transformed 32Dcl3 myeloid precursor cells (unpublished observation). Together, these data suggest that the La-dependent translational stimulation of MDM2 expression might be relevant in the enhanced survival of cancer cells expressing constitutively active tyrosine kinases and might contribute to progression of CML into blast crisis.
Role of the KH-type hnRNPs in controlling differentiation of CML myeloid progenitors La is not the only BCR/ABL-induced RNA binding protein with translation regulatory activity. Indeed, in p210 BCR/ABLexpressing myeloid progenitor cell lines and in mononuclear marrow cells from patients with CML in blast crisis, there is increased expression and function of two KH domain-containing hnRNPs, hnRNP E2 and hnRNP K Perrotti et al., 2004, manuscript in preparation) .
These shuttling RNA binding proteins together with hnRNP E1 form the hnRNP subfamily of the K homology (KH)-domain containing proteins (Makeyev and Liebhaber, 2002) . hnRNP E2 is primarily localized in the cytoplasm, binds C-rich regions in the 5 0 or 3 0 UTR of cellular and viral mRNAs (Blyn et al., 1997; Ostareck et al., 1997; Collier et al., 1998; Graff et al., 1998; Silvera et al., 1999) , and functions primarily as a negative regulator of translation (but a positive effect on translation of viral mRNAs has been reported). Likewise, hnRNP K is also a poly(rC)-binding hnRNP that reportedly regulates mRNA transcription, trafficking and translation (Bomsztyk et al., 1997) . It binds RNA through three repeats of an evolutionary conserved motif termed the KH (K homology) domain, and its nucleocytoplasmic shuttling activity depends on the integrity of a 67 amino-acid motif, the KNS (hnRNP Knuclear shuttling) domain (Michael et al., 1997) . Nevertheless, hnRNP K binds also DNA in a sequencespecific manner consistent with its role in regulation of gene transcription (Tomonaga and Levens, 1996; Gaillard et al., 1994) . hnRNP K enhances c-myc transcription upon binding to a cis element in the cmyc promoter (Takimoto et al., 1993; Lee et al., 1996; Michelotti et al., 1996) . By contrast, it inhibits C/EBPdependent transactivation by directly interacting with C/ EBP itself (Miau et al., 1998) . hnRNP K also functions as a docking platform in proto-oncogene(s)-mediated signaling. For example, through a proline-rich element, hnRNP K interacts with the SH3 domain of p95Vav (Bustelo et al., 1995) and of c-Src (Taylor and Shallo way, 1994; Bustelo et al., 1995) . In addition, PKC (Schullery et al., 1999) and MAPK/ERK (Habelhah et al., 2001 ) phosphorylate hnRNP K on serine 302 and on serines 284/353, respectively. While hnRNP K-Vav interaction may be relevant for Vav-transforming activity (Groysman et al., 1998) , the importance of hnRNP K phosphorylation by PKC for hnRNP K function as regulator of mRNA metabolism is still unclear. By contrast, Src-and ERK-dependent hnRNP K phosphorylation seems to regulate the translation of the mRNAs that, like the 15-lipoxygenase (LOX) mRNA, contain in their 3 0 UTR the CT-rich DICE (differentiation control element) motif (Habelhah et al., 2001; Ostareck-Lederer et al., 2002) . Indeed, mutation at the ERK-phosphoacceptor site in hnRNP K abolishes the ability of hnRNP K to accumulate in the cytoplasm and impairs its ability to function as a silencer of LOX mRNA translation in immature erythroid precursor cells (Habelhah et al., 2001; Ostareck et al., 2001 ).
Thus, it is possible that BCR/ABL may alter the normal myeloid differentiation program by increasing hnRNP K transcriptional and/or translational activity. Interestingly, transcriptional increase of c-Myc expression and activation of the MAPK/ERK-dependent signal transduction pathway are features of BCR/ ABL-transformed cells (Sawyers et al., 1992; Matulonis et al., 1993; Stewart et al., 1995; Wong et al., 1995; Zou et al., 1997; Skorski et al., 1998; Cristofano et al., 2001) which may, in part, depend on increased expression/ activity of hnRNP K. By using hnRNP K mutants defective either in the transcription or in the translation regulatory function, we have preliminary evidence suggesting that hnRNP K translational activity is required in vitro for BCR/ABL leukemogenic potential (Perrotti et al., 2004, manuscript in preparation) . Thus, the employment of a recently described microarraybased approach, termed Ribonomics (Keene and Tenenbaum et al., 2002) , would be useful for the identification of those mRNAs that interact with hnRNP K through a DICE element and whose translation is suppressed. This approach was originally developed in Dr. Keene's laboratory where mRNAs interacting with the HuB RNA binding protein were identified (Tenenbaum et al., 2000) . The best illustration of its utility rests in the recent identification of the mRNAs associated with the FMRP RNA binding protein of the fragile X syndrome (Brown et al., 2001) and in the isolation of the hnRNP E2-associated mRNAs in the Ph 1 K562 cell line (Waggoner and Liebhaber, 2003) .
As levels of hnRNP K increase during CML disease progression, it is likely that BCR/ABL might require the translational-regulatory activity of hnRNP K to inhibit translation of the DICE-containing mRNAs that may encode factors that positively regulate differentiation of myeloid cells and, therefore, could counteract the leukemogenic potential of BCR/ABL. This, indeed, might occur in the case of the hnRNP E2-dependent regulation of c/ebpa mRNA translation . C/EBPa expression is essential for granulocytic differentiation from multipotent progenitor cells (Zhang et al., 1997; Radomska et al., 1998) , but is downmodulated in established BCR/ABL-expressing 32Dcl3 lines, in Ph 1 myeloid CML blast crisis cell lines, and in primary bone marrow cells from CML blast crisis patients . The downregulation of C/ EBPa expression correlates with the levels of BCR/ABL, suggesting that the effects are dose-dependent. However, the presence of detectable c/ebpa mRNA but not protein and the decreased neo-synthesis of C/EBPa in BCR-ABL-transformed cells indicate that inhibition of C/ EBPa expression results from defective translation (Figure 2 ). C/EBPa expression has been reported to be regulated by an evolutionarily conserved short uORF (see Figure 2 ) that acts in cis as a translational repressor (Lincoln et al., 1998) . However, a stalling mechanism caused by enhanced translation of the uORF that would prevent reinitiation from the c/ ebpa AUG does not seem to be responsible for decreased C/EBPa synthesis in BCR/ABL-expressing hematopoietic cells. This conclusion is supported by the observation that mutation of the upstream AUG does not restore C/EBPa expression in BCR/ABL cells (Figure 3) .
By contrast, decreased C/EBPa synthesis in BCR-ABL-expressing cells appears to depend on the integrity of the intercistronic region since mutations in this segment allowed more efficient translation from the main AUG (Figure 3 ). Despite the possibility that the 7-nucleotide spacer element controls ribosomes release after termination of the uORF translation (Lincoln et al., 1998) , our data suggest that translation from the main c/ebpa AUG is inhibited by the physical interaction of hnRNP E2 with the intercistronic region of c/ebpa mRNA. The c/ebpa uORF and spacer region has the potential to form a stem-loop secondary structure that, if stabilized by interaction with hnRNP E2, may physically impede the assembly of the initiation complex and consequently the translation from the main AUG (Cazzola and Skoda, 2000) . However, this does not appear to be the mechanism because only the C-rich intercistronic region, but not the integrity of the potential stem-loop structure, was required for interaction of hnRNP E2 with the c/ebpa mRNA binding protein and suppression of c/ebpa translation. Together with hnRNP E1 and hnRNP K, hnRNP E2 has been implicated in regulation of translation upon binding to cytosine-rich regions contained within RNA secondary structures (Thisted et al., 2001) . In particular, hnRNP E1, hnRNP E2, and hnRNP K bound the 3 0 untranslated region of 15-lipoxygenase mRNA and suppressed translation (Ostareck et al., 1997 Ostareck-Lederer et al., 1998) they also inhibited translation of human papillomavirus type 16 L2 mRNA upon interaction with a regulatory element in the 3 0 of L2 mRNA coding sequence (Collier et al., 1998) . Moreover, these proteins have been implicated in regulation of poliovirus and hepatitis A RNA translation upon interaction with the 5 0 -untranslated region (Makeyev and Liebhaber, 2002 and refs therein) . Despite its similarity to hnRNP E2 in sequence and RNA binding characteristics, hnRNP E1 did not form a complex with the c/ebpa mRNA, and its expression was essentially identical in normal and BCR-ABL-expressing cells. The reason for these differences is not known, but it should be noted that hnRNP E2, but not hnRNP E1, bound to the stem-loop IV of the poliovirus RNA 5 0 noncoding region and regulated viral RNA translation in HeLa cells (Blyn et al., 1997) .
hnRNP E2 expression is inversely correlated with that of C/EBPa as hnRNP E2 levels are abundant in CML blast crisis cells, but virtually undetectable in mononuclear marrow cell from CML chronic phase samples. Moreover, hnRNP E2 levels were upregulated by BCR-ABL in a dose-and kinase-dependent manner. Ectopic expression of hnRNP E2 in myeloid progenitor cells led to downmodulation of C/EBPa and G-CSFR, inhibited granulocytic differentiation and, upon treatment with G-CSF, caused apoptotic cell death most probably due to insufficient G-CSFR-dependent signals .
Conclusion

Translational regulation by oncogenic proteins
has not yet been investigated as extensively as other mechanisms regulating gene expression and function. And yet translation regulation may prove as important, if not more important, than other mechanisms because it has the most direct effect in determining protein levels.
As illustrated here, some of the changes in gene expression brought about by modulating the levels of translation-regulating proteins have a profound effect on the phenotype of BCR/ABL-transformed cells. For example, the block in differentiation associated with downregulation of C/EBPa protein levels and the increased survival associated with MDM2-dependent inhibition of the p53 proapoptotic effects are essential features of the highly malignant cell clones of CML blast crisis.
It seems likely that aberrant translation regulation in tumor cells is not limited to BCR/ABL-dependent leukemogenesis, but also involves other activated tyrosine kinases. It is also likely that, in addition to mdm2 and c/ebpa mRNA, there are many more targets for translation regulation that may be identified by the isolation of a specific mRNA subset associated with the various RNA binding proteins overexpressed in tumor cells.
An obvious question raised by the recent discoveries in the emerging field of aberrant translation regulation in tumor cells is whether the interaction of RNA binding BCR/ABL oncoprotein and translational regulation D Perrotti and B Calabretta proteins with 5 0 and 3 0 UTRs of specific mRNAs can provide targets for therapeutic intervention. For example, we may envision several strategies whereby disruption of the hnRNP E2/c/ebpa mRNA 5 0 UTR interaction may lead to activation of endogenous C/ EBPa expression, which, in turn, may promote differentiation and/or suppress proliferation of tumor cells. Such strategies may be directed to hnRNP E2 itself (antisense or RNA interference approaches) or to the RNA binding protein/mRNA interaction (small molecules that may prevent or disrupt the interaction).
Based on the discoveries of the past few years, it is safe to predict that new observations will be made in the field of translation regulation in cancer cells, and that some of them may reveal new targets for therapeutic intervention.
